658 related articles for article (PubMed ID: 37180097)
1. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
2. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
4. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
5. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
6. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
7. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
[TBL] [Abstract][Full Text] [Related]
8. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
[TBL] [Abstract][Full Text] [Related]
10. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
11. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
Prendecki M; Clarke C; Edwards H; McIntyre S; Mortimer P; Gleeson S; Martin P; Thomson T; Randell P; Shah A; Singanayagam A; Lightstone L; Cox A; Kelleher P; Willicombe M; McAdoo SP
Ann Rheum Dis; 2021 Oct; 80(10):1322-1329. PubMed ID: 34362747
[TBL] [Abstract][Full Text] [Related]
12. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
König M; Lorentzen ÅR; Torgauten HM; Tran TT; Schikora-Rustad S; Vaage EB; Mygland Å; Wergeland S; Aarseth J; Aaberge IAS; Torkildsen Ø; Holmøy T; Berge T; Myhr KM; Harbo HF; Andersen JT; Munthe LA; Søraas A; Celius EG; Vaage JT; Lund-Johansen F; Nygaard GO
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):19-22. PubMed ID: 34670844
[TBL] [Abstract][Full Text] [Related]
13. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma-affected patients.
Vanni A; Salvati L; Mazzoni A; Lamacchia G; Capone M; Francalanci S; Kiros ST; Cosmi L; Puccini B; Ciceri M; Sordi B; Rossolini GM; Annunziato F; Maggi L; Liotta F
Front Immunol; 2023; 14():1322594. PubMed ID: 38106404
[TBL] [Abstract][Full Text] [Related]
15. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
[TBL] [Abstract][Full Text] [Related]
16. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
17. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
18. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.
Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V
Front Immunol; 2023; 14():1296148. PubMed ID: 38259440
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
20. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]